Amiloidosis cardíaca: el rol de la multiimagen, desde lo simple a lo complejo
DOI:
https://doi.org/10.37615/retic.n4a5Palabras clave:
amiloidosis cardíaca, multiimagen cardíaca, strain longitudinal global, resonancia magnética cardíaca.Resumen
Se presenta una revisión exhaustiva de la amiloidosis cardíaca focalizada en el rol de la multiimagen a propósito de un caso.
Descargas
Métricas
Citas
Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013; 6: 1066 – 72. DOI: https://doi.org/10.1161/CIRCIMAGING.113.000683
Zamorano JL, Lancellotti P, Rodríguez Muñoz DR, et al. 2016 ESC Position paper on cáncer treatments and ardiovascular toxicity developed under the auspices of the ESC Comittee for Practice Guidelines. Eur Heart J. 2016; 37 (36): 2768 – 801. DOI: https://doi.org/10.1093/eurheartj/ehw211
Falk R, Alexander K, Liao R, et al. AL (Light-chain) cardiac amyloidosis. A review of diagnosis and therapy. J Am Coll Cardiol. 2016; 68: 1323 – 41. DOI: https://doi.org/10.1016/j.jacc.2016.06.053
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349: 583 – 96. DOI: https://doi.org/10.1056/NEJMra023144
Ng B, Connors L, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure A comparisson with light chain-associated amyloidosis. Arch Int Med. 2005; 165: 1425 – 29. DOI: https://doi.org/10.1001/archinte.165.12.1425
Quarta C, Solomon S, Uraizee I, et al. Left ventricular structure and function in Transthyretin-related versus Light-chain cardiac amyloidosis. Circulation. 2014; 129: 1840 – 9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.006242
Campanile A, Sozzi F, Canetta C, et al. Cardioverter-defibrillator implantation in mieloma-associated cardiac amyloidosis. Exp Clinical Cardiol. 2013; 18 (1): 31 – 4.
Kojima T, Imai Y, Fujiu K, et al. Anti.arrhythmic device therapy has limits in improving the prognosis of patients with cardiac amyloidosis. J Arrhythm. 2012; 28: 242 – 46. DOI: https://doi.org/10.1016/j.joa.2012.01.002
Selvanayagam J, Hawkins P, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007; 50: 2101 – 10. DOI: https://doi.org/10.1016/j.jacc.2007.08.028
Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013; 305: H95-103. DOI: https://doi.org/10.1152/ajpheart.00186.2013
Syed I, Glockner J, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img. 2010; 3: 155 – 64. DOI: https://doi.org/10.1016/j.jcmg.2009.09.023
Murtagh B, Hammill S, Gertz M, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95: 535 – 7. DOI: https://doi.org/10.1016/j.amjcard.2004.10.028
Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltajes in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18: 271 – 80. DOI: https://doi.org/10.1111/anec.12036
Kruszelnicka O, Chmiela M, Razny M, et al. Cardiac AL amyoloidosis. JRCD. 2016; 2: 245 – 53. DOI: https://doi.org/10.20418/jrcd.vol2no8.246
Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional spleckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98: 1442 – 8. DOI: https://doi.org/10.1136/heartjnl-2012-302353
Ternacle J, Bodez D, Guellich A, et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. J Am Coll Cardiol Img. 2016; 9: 126 – 38. DOI: https://doi.org/10.1016/j.jcmg.2015.05.014
Salinaro F, Meier-Ewert H, Miller E, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiol Img. 2016; 0: 1 – 8.
Buss S, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012; 60: 1067 – 76. DOI: https://doi.org/10.1016/j.jacc.2012.04.043
Fontana M, Chung R, Hawkins P, et al. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015; 20: 133 – 44. DOI: https://doi.org/10.1007/s10741-014-9470-7
Pozo E, Kanwar A, Deochand R, et al. Cadiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart. 2014; 100: 1688 – 95. DOI: https://doi.org/10.1136/heartjnl-2014-305710
Maceira A, Joshi J, Prasad S, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111: 186 – 93. DOI: https://doi.org/10.1161/01.CIR.0000152819.97857.9D
Banypersad S, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015; 36: 244 – 51. DOI: https://doi.org/10.1093/eurheartj/ehu444
Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circula- tion. 2015; 132: 1570 – 9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.016567
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2017 Carlos Izurieta, Alfredo Larraburu, Facundo Verón, Luis Gariglio, Juan Pablo Rezzónico, Sergio Muryan
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
RETIC se distribuye bajo la licencia Creative Commons Reconocimiento-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0 que permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
- Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
- No comercial: no puede utilizar el material con fines comerciales.
- No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
- Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
